Loading...
Basilea Pharmaceutica AG
BPMUF•PNK
Healthcare
Biotechnology
$71.00
$0.00(0.00%)
U.S. Market opens in 9h 40mBasilea Pharmaceutica AG (BPMUF) AI-Powered Stock Analysis
See how Basilea Pharmaceutica AG scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerBasilea Pharmaceutica AG (BPMUF) Stock Overall Grade
Basilea Pharmaceutica AG’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Basilea Pharmaceutica AG's overall stock rating.
Forecast
A+Score
100/100Financial Growth
A+Score
95/100Fundamental Growth
B+Score
72/100Key Ratios
A+Score
94/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
96/100Analyst Consensus
B+Score
75/100Basilea Pharmaceutica AG (BPMUF) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 100/100 (A+), reflecting high confidence in its potential. Financial Growth (95/100, A+) and Fundamental Growth (72/100, B+) highlight its stability, while Key Ratios (94/100, A+) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (96/100, A+), it shows competitive strength. Analyst Consensus (75/100,B+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Basilea Pharmaceutica AG stock grade, including financials, comparisons, and forecasts.